文献速递认知障碍与痴呆

整合MRI体积与血浆p-Tau217对早期阿尔茨海默病淀粉样蛋白风险分层

Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease.
PubMed 文献 · Neurology · 2025-08-19

该前瞻性队列研究在K-ROAD和ADNI队列中,对轻度认知障碍或早期阿尔茨海默型痴呆患者,采用基于MRI脑萎缩模式和APOE ε4状态的随机森林分类器进行风险分层,仅中危组接受血浆p-tau217检测,以预测Aβ PET阳性。结果显示该两阶段流程总体准确率在K-ROAD为94.2%、ADNI为96.5%,低危组阴性预测值分别达94.7%和99.0%,高危组阳性预测值分别达97.6%和98.8%,中危组仅占33.3%和20.9%。

要点

  • MRI风险分层可高效预测早期AD的Aβ PET阳性,低危组NPV达94.7%-99.0%。
  • 仅中危组需血浆p-tau217检测,该组占比33.3%(K-ROAD)和20.9%(ADNI)。
  • 两阶段流程总体准确率94.2%-96.5%,减少额外生物标志物检测需求。

核心结论

  • 整合MRI风险分层与血浆p-tau217的两阶段诊断流程能准确识别早期AD中Aβ PET阳性个体,并显著减少额外生物标志物检测需求。

研究设计与样本

  • 前瞻性队列研究,纳入K-ROAD队列807例(中位年龄72.0岁,女性58.7%)和ADNI队列230例(中位年龄70.9岁,女性49.1%)的MCI或早期ATD患者,临床痴呆评分为0.5,且具备MRI、血浆p-tau217和Aβ PET数据。

主要发现

  • 低危组NPV在K-ROAD为94.7%(91.7%-97.7%),在ADNI为99.0%(97.0%-100.0%)。
  • 高危组PPV在K-ROAD为97.6%(95.9%-99.3%),在ADNI为98.8%(96.5%-100.0%)。
  • 中危组在K-ROAD占33.3%、在ADNI占20.9%,其血浆p-tau217检测PPV分别为92.5%(88.7%-96.3%)和90.0%(79.0%-100.0%),NPV分别为83.1%(75.0%-91.2%)和83.3%(66.1%-100.0%)。
  • 整体流程准确率在K-ROAD为94.2%(92.6%-95.8%),在ADNI为96.5%(94.1%-98.9%)。

关键数值与推荐

  • 采用95%灵敏度/特异度策略设定风险分层阈值。
  • 随机森林分类器基于MRI脑萎缩模式和APOE ε4状态预测Aβ PET阳性。
  • 仅中危组个体接受血浆p-tau217检测。

临床怎么用

  • 在早期AD认知评估中,可先以常规MRI特征进行风险分层,低危组可考虑暂缓Aβ PET,高危组可直接提示Aβ阳性,仅中危组需加做血浆p-tau217以明确。

局限性

  • 相对于基线模型的增量改善有限,可能限制泛化能力。
  • 队列种族和民族多样性有限,可能影响结果外推。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Identifying β-amyloid (Aβ) positivity is crucial for selecting candidates for Aβ-targeted therapies in early-stage Alzheimer disease (AD). While Aβ PET is accurate, its high cost limits routine use. Plasma p-tau217 testing offers a less invasive option but also incurs additional costs. Structural brain MRI, routinely used in cognitive assessments, can identify features predictive of Aβ positivity without extra expense. We evaluated a 2-stage workflow integrating MRI-based features and plasma p-tau217 to efficiently predict Aβ PET positivity in early-stage AD. METHODS: This prospective cohort study included participants with mild cognitive impairment (MCI) or early Alzheimer-type dementia (ATD) from the Korea-Registries to Overcome Dementia and Accelerate Dementia Research (K-ROAD; Korea) and Alzheimer's Disease Neuroimaging Initiative (ADNI; US) cohorts. Eligible participants had a Clinical Dementia Rating score of 0.5, along with MRI, plasma p-tau217, and Aβ PET data. A random forest classifier predicting Aβ PET positivity was developed using MRI-based brain atrophy patterns and APOE ε4 status. Participants were stratified into low-risk, intermediate-risk, and high-risk groups; plasma p-tau217 testing was performed only in intermediate-risk individuals. Outcomes included positive predictive value (PPV), negative predictive value (NPV), and overall accuracy. RESULTS: A total of 807 K-ROAD participants (median age 72.0 years, 58.7% female) and 230 ADNI participants (median age 70.9 years, 49.1% female) were analyzed. Using a 95% sensitivity/specificity strategy, the low-risk group demonstrated NPVs of 94.7% (91.7%-97.7%, K-ROAD) and 99.0% (97.0%-100.0%, ADNI). The high-risk group showed PPVs of 97.6% (95.9%-99.3%, K-ROAD) and 98.8% (96.5%-100.0%, ADNI). Intermediate-risk groups comprised 33.3% (K-ROAD) and 20.9% (ADNI) of participants. Plasma p-tau217 testing in intermediate-risk groups yielded PPVs of 92.5% (88.7%-96.3%, K-ROAD) and 90.0% (79.0%-100.0%, ADNI) and NPVs of 83.1% (75.0%-91.2%, K-ROAD) and 83.3% (66.1%-100.0%, ADNI). The overall workflow accuracy was 94.2% (92.6%-95.8%, K-ROAD) and 96.5% (94.1%-98.9%, ADNI). DISCUSSION: The 2-stage diagnostic workflow integrating MRI-based risk stratification and plasma p-tau217 testing accurately identified individuals with Aβ PET positivity in early-stage AD, substantially reducing the need for additional biomarker testing. However, the generalizability may be limited by modest incremental improvement over baseline models and limited racial and ethnic diversity.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Yim S, Park S, Lim K, et al. Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease. Neurology. 2025. PMID: 40829110. doi:10.1212/WNL.0000000000213954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。